The abstract is read at the publisher; the summary is JClub's.
Quantitative CD19 density measured before CAR T-cell infusion stratifies progression-free survival in large B-cell lymphoma, with low CD19 density linked to CAR T-cell escape.
- Why it matters: The field needs to explain why some large B-cell lymphoma patients relapse after CD19 CAR T-cell therapy, especially when low antigen is observed.
- What they did: Corona, Gillmor, and colleagues measured CD19 density prior to infusion and analyzed its relationship to progression-free survival; Newsam and colleagues examined recurrent del(3p21.31)/RHOA loss and its effect on CD19 and CAR T-cell efficacy.
- The result: Low CD19 density predicts poorer progression-free survival, while it is rarely due to a CD19 locus genetic lesion, implying other mechanisms of CD19 downregulation drive escape.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.